Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia
Clinical Gastroenterology and Hepatology · 2026-07 · 24 (7) · 2007-2018
DOI: 10.1016/j.cgh.2025.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-07. Verfasst von Aasma Shaukat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, NYU Grossman School of Medicine, New York, New York; Department of Medicine, VA New York Harbor Health Care System, New…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer, Mass Screening, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND & AIMS: This study assessed the economic and health impact of colorectal cancer (CRC) screening programs for average-risk individuals aged 45 years and older. METHODS: A 10-year Markov model simulated disease progression, comparing multitarget stool RNA test (mt-sRNA, ColoSense), two mt-sDNA tests (Cologuard and Cologuard Plus), a blood-based test (cfDNA, Shield), and a fecal immunochemical test (FIT). Clinical inputs leveraged age-weighted sensitivity and specificity from independent studies. Outcomes were compared with a colonoscopy-based program and no screening. Model calibration and validation used previously reported Cancer Intervention Surveillance Modeling Network (CISNET) models. RESULTS: Among molecular tests, mt-sRNA detected the most advanced adenomas, referred the most individuals to surveillance, and prevented the highest number of CRC cases and deaths. At real-world adherence of 60%, mt-sRNA reduced CRC cases and deaths by 1% and 14% compared with FIT; by 21% and 19% compared with mt-sDNA; by 28% and 23% compared with mt-sDNA+; and by 80% and 86% compared with cfDNA. For all adherence levels, FIT ($25/test) was the most cost-effective strategy. For triennial molecular tests ($509/test), mt-sRNA was the most cost-effective strategy. Relative to the mt-sRNA program, the cost to prevent a CRC case was 30% (mt-sDNA), 45% (mt-sDNA+), and 642% (cfDNA) more expensive. Relative to the mt-sRNA program, the cost to prevent a CRC death was 30% (mt-sDNA), 41% (mt-sDNA+), and 1040% (cfDNA) more expensive. CONCLUSIONS: FIT was the most cost-effective strategy for preventing CRC cases and deaths. At real-world adherence of 60%, mt-sRNA demonstrated the greatest clinical benefit and was more cost-effective than other molecular strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, NYU Grossman School of Medicine, New York, New York; Department of Medicine, VA New York Harbor Health Care System, New York, New York.
- Kaiser Permanente Division of Research, Pleasanton, California.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
- Precision AQ, London, United Kingdom.
- Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri; Geneoscopy Inc, Saint Louis, Missouri. Electronic address: e.barnell@wustl.edu.
Zitieren
APA
Shaukat, A., Levin, T. R., Liang, P. S., Weiss, J. M., Smare, C., Boller, E., Venkatachalam, M., & Barnell, E. K. (2026). Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 24(7), 2007-2018. https://doi.org/10.1016/j.cgh.2025.06.006
Vancouver
Shaukat A, Levin TR, Liang PS, Weiss JM, Smare C, Boller E, et al. Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia. Clinical Gastroenterology and Hepatology. 2026;24(7):2007-2018. doi:10.1016/j.cgh.2025.06.006
BibTeX
@article{Shaukat2026,
author = {Shaukat, Aasma and Levin, Theodore R and Liang, Peter S and Weiss, Jennifer M and Smare, Caitlin and Boller, Emily and Venkatachalam, Meena and Barnell, Erica K},
title = {Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {7},
pages = {2007--2018},
doi = {10.1016/j.cgh.2025.06.006}
}
EUVIMED